• Clario accelerates your clinical trial from initiation to implementation. LEARN MORE →

Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)

      Discover Clario's AI solutions, where innovation meets expertise. Since 2018, we have revolutionized clinical trial endpoint analyses with more than 30 AI-enabled solutions across 600+ active trials, enhancing data quality and patient privacy while expediting data collection processes.

      Go to page
    • Cardiac Safety
      • Cardiac Safety
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Image Repository
      • Imaging Platform
      • Image Workflow
      • Modalities
      • SMART Submit
    • Precision Motion for Clinical Trials
      • Precision Motion for Clinical Trials
      • Precision Motion: Scientific Consulting Services
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, etc.)
      • Home & Hybrid DCT Spirometry​
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials

      All the precision endpoint technology and services your virtual or hybrid trial needs to deliver more certain outcomes.

      Go to page
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology Clinical Trials
    • Ophthalmology
    • Respiratory Solutions
  • Resources
    • Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Security Governance
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)
    • Cardiac Safety
      • Cardiac Safety
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Image Repository
      • Imaging Platform
      • Image Workflow
      • Modalities
      • SMART Submit
    • Precision Motion for Clinical Trials
      • Precision Motion for Clinical Trials
      • Precision Motion: Scientific Consulting Services
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, etc.)
      • Home & Hybrid DCT Spirometry​
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials
      • Decentralized Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology Clinical Trials
    • Ophthalmology
    • Respiratory Solutions
  • Resources
    • Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Security Governance
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home About Newsroom Clario endorses United Nations Global Compact, affirming commitment to incorporate UN principles into corporate strategy, culture and daily operations

Clario endorses United Nations Global Compact, affirming commitment to incorporate UN principles into corporate strategy, culture and daily operations

Leading clinical trial endpoint technology provider takes steps to accelerate improvements in human rights, labor, environment and anti-corruption

PHILADELPHIA, PA – April 14, 2022 – Clario, a technology company that delivers the leading endpoint technology solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced that it has become a signatory to the United Nations (UN) Global Compact. By joining this voluntary initiative, Clario commits to advance societal goals by aligning its strategy and operations with the UN Ten Principles on human rights, labor, environment and anti-corruption.

“We are proud to be a part of the UN Global Compact,” explained Joe Eazor, Clario’s Chief Executive Officer. Clario’s purpose is to transform lives by unlocking better evidence. Our work means more people from more diverse backgrounds can take part in clinical trials to reduce disease, improve health and transform the lives of patients and their families. This aligns closely with the UN’s Global Compact challenge to companies to create a more equitable and sustainable society.

“We have already incorporated several of the Ten Principles into our company policies and culture, including: eliminating discrimination in respect to employment and occupation; encouraging the development and diffusion of environmentally friendly technologies; and working against corruption in all its forms, including extortion and bribery.”

Participation in the UN Global Compact is a critical part of Clario’s overall Environmental, Social and Governance (ESG) program which also includes commitments to reduce greenhouse gas emissions and to advance the UN Sustainable Development Goals (SDGs), the UN call to action to end poverty, protect the planet and ensure peace and prosperity.

“Through our collaboration with the UN and other organizations that focus on diversity, equity, inclusion and sustainability, we do our part to promote social progress. That’s why joining the Global Compact is a natural next step for Clario,” said Dr. Otis Johnson, Clario’s Chief Diversity, Inclusion and Sustainability Officer. “Transparency and public accountability are an important part of how companies deliver on their social and environmental obligations, which is why it is already a vital part of Clario’s culture to report to our employees and partners. Of course, as a company we want to do well, but we believe we can only do well by also doing good.”


About the UN Global Compact

Launched in 2000 as a special initiative of the UN Secretary-General, the United Nations (UN) Global Compact is the largest corporate sustainability initiative in the world, with over 10,000 companies and 3,000 non-business signatories based in over 160 countries.

About Clario

For nearly 50 years, Clario has been delivering the leading endpoint technology solutions for clinical trials. Through experience gained from over 19,000 clinical trials delivered in support of 870 regulatory approvals, Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to empower pharmaceutical, biotech and medical device partners to transform lives. Clario’s solutions have been powering hybrid and decentralized clinical trials (DCT) for over 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving the patient experience. Clario has 30 facilities in nine countries across North America, Europe and Asia Pacific.

Clario Media Contact

Duncan Cantor
Sr. Director, PR and Thought Leadership
[email protected]

Back to news
Share
Twitter Facebook LinkedIn

Latest News

See all news

Clario teams up with CellCarta to transform clinical trial sample management for histopathology studies

September 26, 2023 Read more

Clario Reveals Updated Oncology Trial Solutions Portfolio: The Industry’s Widest Range of Endpoint Collection Technologies

September 1, 2023 Read more

Dr. Vince Clinical Research, Clario Form Strategic Partnership to Deliver Innovative Cardiac Assessments in Clinical Trials

August 29, 2023 Read more
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

Thanks for your form. Our team will be in touch very soon.

  • © 2023 Clario

    • Legal and Privacy Terms
    • Security Governance
    • Cookie Policy
    • Impressum

Please enter your business email before proceeding to xTalks to complete registration.

×